Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Cellectar Biosciences management to meet virtually with Oppenheimer » 04:55
05/07/21
05/07
04:55
05/07/21
04:55
CLRB

Cellectar Biosciences

$1.37 /

-0.1 (-6.80%)

Virtual Meeting to be…

Virtual Meeting to be held on May 7 hosted by Oppenheimer.

ShowHide Related Items >><<
CLRB Cellectar Biosciences
$1.37 /

-0.1 (-6.80%)

CLRB Cellectar Biosciences
$1.37 /

-0.1 (-6.80%)

04/27/21 Roth Capital
Cellectar strengthens IP estate as CLR 131 trial progresses, says Roth Capital
07/01/20 Oppenheimer
Oppenheimer bullish on Cellectar Biosciences, initiates with an Outperform
07/01/20 Oppenheimer
Cellectar Biosciences initiated with an Outperform at Oppenheimer
06/23/20
Fly Intel: Top five analyst initiations
CLRB Cellectar Biosciences
$1.37 /

-0.1 (-6.80%)

  • 23
    Dec
Tuesday
Conference/Events
Cellectar Biosciences management to meet virtually with Oppenheimer » 10:28
05/04/21
05/04
10:28
05/04/21
10:28
CLRB

Cellectar Biosciences

$1.51 /

-0.16 (-9.58%)

Virtual Meeting to be…

Virtual Meeting to be held on May 7 hosted by Oppenheimer.

ShowHide Related Items >><<
CLRB Cellectar Biosciences
$1.51 /

-0.16 (-9.58%)

CLRB Cellectar Biosciences
$1.51 /

-0.16 (-9.58%)

04/27/21 Roth Capital
Cellectar strengthens IP estate as CLR 131 trial progresses, says Roth Capital
07/01/20 Oppenheimer
Oppenheimer bullish on Cellectar Biosciences, initiates with an Outperform
07/01/20 Oppenheimer
Cellectar Biosciences initiated with an Outperform at Oppenheimer
06/23/20
Fly Intel: Top five analyst initiations
CLRB Cellectar Biosciences
$1.51 /

-0.16 (-9.58%)

  • 23
    Dec
Over a week ago
Conference/Events
Cellectar Biosciences management to meet virtually with Oppenheimer » 10:51
04/30/21
04/30
10:51
04/30/21
10:51
CLRB

Cellectar Biosciences

$1.54 /

+ (+0.00%)

Virtual Meeting to be…

Virtual Meeting to be held on April 30 hosted by Oppenheimer.

ShowHide Related Items >><<
CLRB Cellectar Biosciences
$1.54 /

+ (+0.00%)

CLRB Cellectar Biosciences
$1.54 /

+ (+0.00%)

04/27/21 Roth Capital
Cellectar strengthens IP estate as CLR 131 trial progresses, says Roth Capital
07/01/20 Oppenheimer
Oppenheimer bullish on Cellectar Biosciences, initiates with an Outperform
07/01/20 Oppenheimer
Cellectar Biosciences initiated with an Outperform at Oppenheimer
06/23/20
Fly Intel: Top five analyst initiations
CLRB Cellectar Biosciences
$1.54 /

+ (+0.00%)

  • 23
    Dec
Recommendations
Cellectar strengthens IP estate as CLR 131 trial progresses, says Roth Capital » 11:35
04/27/21
04/27
11:35
04/27/21
11:35
CLRB

Cellectar Biosciences

$1.57 /

-0.01 (-0.63%)

Roth Capital analyst…

Roth Capital analyst Jonathan Aschoff notes Cellectar Biosciences was granted a patent titled "Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles" in Eurasia, Australia and Mexico, giving composition of matter and use protection to its proprietary phospholipid-ether analogs as a targeted delivery vehicle in combination with chemotherapeutic classes such as alkaloids, nucleoside analogs, and other small molecule chemotherapeutics. The analyst also points out that the company is funded through mid-2023, and lead drug CLR 131 progresses through its pivotal WM trial, with results expected in Q3 of 2022. Aschoff has a Buy rating and a price target of $10 on the shares.

ShowHide Related Items >><<
CLRB Cellectar Biosciences
$1.57 /

-0.01 (-0.63%)

CLRB Cellectar Biosciences
$1.57 /

-0.01 (-0.63%)

07/01/20 Oppenheimer
Oppenheimer bullish on Cellectar Biosciences, initiates with an Outperform
07/01/20 Oppenheimer
Cellectar Biosciences initiated with an Outperform at Oppenheimer
06/23/20
Fly Intel: Top five analyst initiations
06/23/20 Maxim
Cellectar Biosciences initiated with a Buy at Maxim
CLRB Cellectar Biosciences
$1.57 /

-0.01 (-0.63%)

  • 23
    Dec
Hot Stocks
Cellectar receives notification of grant of composition of matter patent » 08:42
04/27/21
04/27
08:42
04/27/21
08:42
CLRB

Cellectar Biosciences

$1.58 /

+ (+0.00%)

Cellectar Biosciences…

Cellectar Biosciences announced that it has received notification of formal grant of the patent titled, "Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles" by the Eurasian, Australian and Mexican patent authorities. This patent provides composition of matter and use protection for the company's proprietary phospholipid-ether analogs as a targeted delivery vehicle in combination with a broad range of commonly used chemotherapeutic classes such as alkaloids, nucleoside analogs, as well as other classes of small molecule chemotherapeutic agents. The cancer-targeting PLE delivery vehicle serves as the foundation for the company's research, development and pipeline including CLR 131, our lead product candidate. CLR 131 is currently in multiple clinical studies, including a pivotal registrational study in Waldenstrom's macroglobulinemia, a Phase 2b study in multiple myeloma, and a Phase 1 study in multiple pediatric solid tumor indications.

ShowHide Related Items >><<
CLRB Cellectar Biosciences
$1.58 /

+ (+0.00%)

CLRB Cellectar Biosciences
$1.58 /

+ (+0.00%)

07/01/20 Oppenheimer
Oppenheimer bullish on Cellectar Biosciences, initiates with an Outperform
07/01/20 Oppenheimer
Cellectar Biosciences initiated with an Outperform at Oppenheimer
06/23/20
Fly Intel: Top five analyst initiations
06/23/20 Maxim
Cellectar Biosciences initiated with a Buy at Maxim
CLRB Cellectar Biosciences
$1.58 /

+ (+0.00%)

  • 23
    Dec
Conference/Events
Cellectar Biosciences management to meet virtually with Oppenheimer » 04:55
04/23/21
04/23
04:55
04/23/21
04:55
CLRB

Cellectar Biosciences

$1.50 /

+0.015 (+1.01%)

Virtual Meeting to be…

Virtual Meeting to be held on April 23 hosted by Oppenheimer.

ShowHide Related Items >><<
CLRB Cellectar Biosciences
$1.50 /

+0.015 (+1.01%)

CLRB Cellectar Biosciences
$1.50 /

+0.015 (+1.01%)

07/01/20 Oppenheimer
Oppenheimer bullish on Cellectar Biosciences, initiates with an Outperform
07/01/20 Oppenheimer
Cellectar Biosciences initiated with an Outperform at Oppenheimer
06/23/20
Fly Intel: Top five analyst initiations
06/23/20 Maxim
Cellectar Biosciences initiated with a Buy at Maxim
CLRB Cellectar Biosciences
$1.50 /

+0.015 (+1.01%)

  • 23
    Dec
Conference/Events
Cellectar Biosciences management to meet virtually with Oppenheimer » 10:10
04/22/21
04/22
10:10
04/22/21
10:10
CLRB

Cellectar Biosciences

$1.46 /

-0.02 (-1.35%)

Virtual Meeting to be…

Virtual Meeting to be held on April 23 hosted by Oppenheimer.

ShowHide Related Items >><<
CLRB Cellectar Biosciences
$1.46 /

-0.02 (-1.35%)

CLRB Cellectar Biosciences
$1.46 /

-0.02 (-1.35%)

07/01/20 Oppenheimer
Oppenheimer bullish on Cellectar Biosciences, initiates with an Outperform
07/01/20 Oppenheimer
Cellectar Biosciences initiated with an Outperform at Oppenheimer
06/23/20
Fly Intel: Top five analyst initiations
06/23/20 Maxim
Cellectar Biosciences initiated with a Buy at Maxim
CLRB Cellectar Biosciences
$1.46 /

-0.02 (-1.35%)

  • 23
    Dec
Over a month ago
Hot Stocks
Cellectar Biosciences granted Japanese composition of matter patent » 09:13
03/09/21
03/09
09:13
03/09/21
09:13
CLRB

Cellectar Biosciences

$1.74 /

-0.005 (-0.29%)

Cellectar Biosciences…

Cellectar Biosciences announced that the Japan Patent Office has granted patent number 6832861, titled, "Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles." The patent provides composition of matter and use protection for the company's proprietary phospholipid-ether, targeted delivery vehicle analogs in combination with a broad range of commonly used chemotherapeutic classes such as alkaloids, nucleoside analogs, as well as other classes of small molecule chemotherapeutic agents. The cancer-targeting PLE delivery vehicle serves as the foundation for the company's research, development and pipeline including lead product candidate CLR 131, which continues to advance through clinical studies in both adult and pediatric cancer indications.

ShowHide Related Items >><<
CLRB Cellectar Biosciences
$1.74 /

-0.005 (-0.29%)

CLRB Cellectar Biosciences
$1.74 /

-0.005 (-0.29%)

07/01/20 Oppenheimer
Oppenheimer bullish on Cellectar Biosciences, initiates with an Outperform
07/01/20 Oppenheimer
Cellectar Biosciences initiated with an Outperform at Oppenheimer
06/23/20
Fly Intel: Top five analyst initiations
06/23/20 Maxim
Cellectar Biosciences initiated with a Buy at Maxim
CLRB Cellectar Biosciences
$1.74 /

-0.005 (-0.29%)

  • 23
    Dec
Hot Stocks
Cellectar Biosciences expects cash to fund operations for at least 12 months » 08:34
03/02/21
03/02
08:34
03/02/21
08:34
CLRB

Cellectar Biosciences

$1.90 /

+0.045 (+2.43%)

Cash and Cash…

Cash and Cash Equivalents: As of December 31, 2020, the company had cash and cash equivalents of $57.2 million compared to $10.6 million at December 31, 2019. Cash provided by financing activities was $60.5 million, offset by cash used in operating activities of $13.9 million. The company believes its cash on hand is adequate to fund basic budgeted operations for at least 12 months from the filing of these financial statements.

ShowHide Related Items >><<
CLRB Cellectar Biosciences
$1.90 /

+0.045 (+2.43%)

CLRB Cellectar Biosciences
$1.90 /

+0.045 (+2.43%)

07/01/20 Oppenheimer
Oppenheimer bullish on Cellectar Biosciences, initiates with an Outperform
07/01/20 Oppenheimer
Cellectar Biosciences initiated with an Outperform at Oppenheimer
06/23/20
Fly Intel: Top five analyst initiations
06/23/20 Maxim
Cellectar Biosciences initiated with a Buy at Maxim
CLRB Cellectar Biosciences
$1.90 /

+0.045 (+2.43%)

  • 23
    Dec
Hot Stocks
Cellectar Biosciences reports 2020 EPS (76c), consensus (83c) » 08:33
03/02/21
03/02
08:33
03/02/21
08:33
CLRB

Cellectar Biosciences

$1.90 /

+0.045 (+2.43%)

"2020 was an…

"2020 was an important year for Cellectar, having announced key data from our Phase 2a CLOVER-1 study; having gained clarity on our Waldenstrom's macroglobulinemia regulatory strategy after a positive meeting with the FDA in the Fall; and having completed a successful capital raise to support our WM pivotal study to our anticipated marketing approval date," said James Caruso, president and CEO of Cellectar. "We are fully engaged in the execution our CLR 131 clinical programs, prioritizing the WM pivotal study, enriching our refractory multiple myeloma data sets, and advancing our pediatric study. In parallel, we continue our research to better understand the unique potential of our delivery platform and look forward to sharing additional data."

ShowHide Related Items >><<
CLRB Cellectar Biosciences
$1.90 /

+0.045 (+2.43%)

CLRB Cellectar Biosciences
$1.90 /

+0.045 (+2.43%)

07/01/20 Oppenheimer
Oppenheimer bullish on Cellectar Biosciences, initiates with an Outperform
07/01/20 Oppenheimer
Cellectar Biosciences initiated with an Outperform at Oppenheimer
06/23/20
Fly Intel: Top five analyst initiations
06/23/20 Maxim
Cellectar Biosciences initiated with a Buy at Maxim
CLRB Cellectar Biosciences
$1.90 /

+0.045 (+2.43%)

  • 23
    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.